Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen

Blood (2023) 142 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2023-181937

Published: 2023

Journal Articles

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Maria Agustina Perusini, Camille Kockerols, Daniela Žáčková, Franck E. Nicolini, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Mary Lynn Savoie, Christophe Bouvier, Petra Čičátková, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Jiří Mayer, Peter E Westerweel, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2023-190293

Published: 2023

Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Blood (2023) 142 (13): 1131–1142.

https://doi.org/10.1182/blood.2023020195

Published: 2023

Includes: Supplemental data

Journal Articles

Detecting measurable residual disease beyond 10 −4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

Paul J. Hengeveld, Michèle Y. van der Klift, P. Martijn Kolijn, Frédéric Davi, François G. Kavelaars, Evert de Jonge, Sandra Robrecht, Jorn L. J. C. Assmann, Lina van der Straten, Matthias Ritgen, Peter E. Westerweel, Kirsten Fischer, Valentin Goede, Michael Hallek, Mark-David Levin, Anton W. Langerak

Blood (2023) 141 (5): 519–528.

https://doi.org/10.1182/blood.2022017411

Published: 2023

Includes: Supplemental data

Journal Articles

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Torsten Dahlén, Camille C.B. Kockerols, Germano Ferreira, Peter E. Westerweel, Jiri Mayer, Alex Allepuz, David Wormser, Lillian Yau, Daniela Žácková

Blood (2022) 140 (Supplement 1): 3889–3890.

https://doi.org/10.1182/blood-2022-163151

Published: 2022

Journal Articles

Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Camille C.B. Kockerols, Peter JM Valk, Nicole M A Blijlevens, Jan J. Cornelissen, Avinash G. Dinmohamed, Inge Geelen, Mels Hoogendoorn, Jeroen J.W.M. Janssen, Laura G.M. Daenen, Bert A. van der Reijden, Peter E. Westerweel

Blood (2022) 140 (Supplement 1): 3887–3888.

https://doi.org/10.1182/blood-2022-168722

Published: 2022

Journal Articles

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Paul Hengeveld, Pieter M. Kolijn, Jeroen A.A. Demmers, Wouter Doff, Julie M.N. Dubois, Melissa Rijken, Jorn Assmann, Lina Van Der Straten, Henk-Jan Boiten, Kirsten J. Gussinklo, Peter J.M. Valk, Peter E. Westerweel, Arnon P. Kater, Anton W. Langerak, Mark-David Levin

Blood (2022) 140 (Supplement 1): 9851–9852.

https://doi.org/10.1182/blood-2022-158881

Published: 2022

Journal Articles

The Effect of COVID-19 Vaccine in Patients with Immune Thrombocytopenia

Chantal Visser, Maurice Swinkels, Erik D. van Werkhoven, F. Nanne Croles, Heike Noordzij, Matthijs Eefting, Suzanne M. Last-Koopmans, Cecile Idink, Peter E. Westerweel, Bart Santbergen, Pieter A. Jobse, Fazil Baboe, Recovac-IR Consortium, Mark-David Levin, Marieke J.H.A. Kruip, A.J. Gerard Jansen

Blood (2021) 138 (Supplement 1): 587.

https://doi.org/10.1182/blood-2021-146529

Published: 2021

Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

Torsten Dahlen, Camille Kockerols, Germano Ferreira, Peter E. Westerweel, Jiří Mayer, Tarek Sahmoud, David Wormser, Lillian Yau, Daniela Žácková

Blood (2021) 138 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2021-148773

Published: 2021

Journal Articles

Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax

Karoline Kielbassa, Marco Haselager, Danique Bax, Julie Dubois, Mark-David Levin, Peter E. Westerweel, Rebecka Svanberg, Carsten Utoft Niemann, Arnon P. Kater, Eric Eldering

Blood (2021) 138 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2021-152222

Published: 2021

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study

Fabrizio Pane, Luigia Luciano, MD, Novella Pugliese, MD, Juan Luis Steegman, Prof, Peter E. Westerweel, MD, Elisabetta Abruzzese, MD, Massimo Breccia, MD, Monica Bocchia, MD PhD, Simona Soverini, PhD, Fausto Castagnetti, MD PhD, Maria Monteverde, Gianantonio Rosti, Giuseppe Saglio, Jeroen J. Janssen, MD PhD

Blood (2018) 132 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2018-99-118925

Published: 2018

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

Inge G.P. Geelen, MD, Noortje Thielen, MD PhD, Jeroen J.W.M. Janssen, MD PhD, Tanja Roosma, Otto Visser, MD PhD, Jan J. Cornelissen, MD PhD, Peter E. Westerweel, MD PhD

Blood (2016) 128 (22): 1913.

https://doi.org/10.1182/blood.V128.22.1913.1913

Published: 2016

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

NARROW

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Detecting measurable residual disease beyond 10 −4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

The Effect of COVID-19 Vaccine in Patients with Immune Thrombocytopenia

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only